A Phase I/II trial shows AMT-130 gene therapy slowed Huntington's disease by 75% over three years, offering the strongest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback